Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Impax

- PMLiVE

GSK’s Jemperli made available to endometrial cancer patients via UK’s early access scheme

Approximately 10,000 new cases of endometrial cancer are reported each year in the UK

- PMLiVE

FDA declines to approve Amneal Pharmaceuticals’ Parkinson’s disease treatment

The regulator said the safety for one of the drug's ingredients had not been adequately established

Bayer symbol

Bayer and BlueRock announce positive early-stage results for Parkinson’s cell therapy

The progressive neurological disorder affects around ten million people worldwide

- PMLiVE

GSK’s RSV vaccine shows long-term efficacy in late-stage older adults study

Arexvy was recently approved in the EU and US for adults aged 60 years and older

- PMLiVE

GSK’s RSV vaccine approved by European Commission for older adults

RSV infections in older adults account for over 170,000 hospitalisations each year in Europe

- PMLiVE

GSK’s five-in-one meningococcal vaccine candidate shows promise in phase 3 trial

There are no approved vaccines offering simultaneous protection against all five serogroups

- PMLiVE

GSK welcomes Canadian court ruling to dismiss Zantac litigation

The company and other drugmakers have been facing thousands of lawsuits claiming ranitidine caused cancer

- PMLiVE

GSK’s RSV vaccine approved by FDA for older adults

Arexvy is the first RSV vaccine for this age group to be approved anywhere in the world

- PMLiVE

CureVac announces start of phase 1/2 seasonal influenza vaccine trial

The multivalent mRNA candidates have been developed in collaboration with GSK

- PMLiVE

GSK’s RSV vaccine candidate recommended by CHMP for older adults

RSV infections in older adults account for over 270,000 hospitalisations each year in Europe

- PMLiVE

GSK to acquire Bellus Health for approximately $2bn

The deal includes the biotech’s late-stage candidate for refractory chronic cough

- PMLiVE

Study unveils ‘breakthrough biomarker’ for Parkinson’s disease

Researchers say they can measure a protein to determine the likelihood that someone will develop the disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links